NCT01441076View on ClinicalTrials.gov

Anakinra for Behcet s Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions
Autoimmune Connective Tissue DisorderImmune System Diseases
Interventions
DRUG

Anakinra

Anakinra/Kineret\[registered\] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT01441076 - Anakinra for Behcet s Disease | Biotech Hunter | Biotech Hunter